<DOC>
	<DOCNO>NCT01134263</DOCNO>
	<brief_summary>The purpose study demonstrate different CYD Dengue vaccine lot manufacture use method location different time produce equivalent immunological response . Primary Objective - To demonstrate three different Phase III lot CYD Dengue vaccine induce equivalent immune response term post-Dose 3 geometric mean titer ( GMTs ) four parental serotypes . Secondary Objectives : - To demonstrate data one Phase II lot pool data Phase III lot CYD Dengue vaccine show equivalent immune response term post-Dose 3 GMTs four parental serotypes . - To describe safety ( term solicit injection site systemic reaction unsolicited adverse event ) CYD Dengue vaccine subject dose .</brief_summary>
	<brief_title>Study Tetravalent Dengue Vaccine Healthy Adults Australia</brief_title>
	<detailed_description>All subject receive 3 dos assign vaccine placebo provide blood sample define timepoints flavivirus status immunogenicity assessment . Reactogenicity data collect subject dose throughout study .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Severe Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 18 60 year day inclusion Informed consent form sign date Able attend schedule visit comply trial procedure For woman childbearing potential , use effective method contraception , abstinence least 4 week prior first vaccination least 4 week last vaccination ( i.e. , 14 month ) . Known pregnancy , positive urine pregnancy test History flavivirus infection vaccination prolong habitation dengue endemic area Currently breastfeed child Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination Planned participation another clinical trial present trial period Planned receipt vaccine 4 week follow trial vaccination , except pandemic influenza vaccination Receipt blood bloodderived product past 3 month , might interfere assessment immune response Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Selfreported seropositivity human immunodeficiency virus ( HIV ) Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use trial vaccine contain substance Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction might interfere ability comply trial procedure Chronic illness , opinion Investigator , stage might interfere trial conduct completion Identified site employee Investigator study center , direct involvement propose study study direction Investigator study center , well family member ( i.e. , immediate , husband , wife child , adopt natural ) site employee Investigator Temporary Contraindications : A prospective subject must include study follow condition and/or symptom resolve : Febrile illness ( temperature ≥ 38.0°C ) moderate severe acute illness/infection ( accord Investigator 's judgment ) day vaccination Receipt vaccine 4 week precede first trial vaccination , except pandemic influenza vaccination , may receive least two week study vaccine Vaccination postpone within timeframe vaccination indicate table study procedure enrolment ongoing site .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Dengue Fever</keyword>
	<keyword>Dengue Hemorrhagic Fever</keyword>
	<keyword>CYD Dengue Vaccine</keyword>
	<keyword>Lot Consistency</keyword>
</DOC>